On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Dr. Anderson has over 7 years of experience in cancer drug discovery and early-stage research. Prior to joining Cleave in early 2012, Dr. Anderson contributed to a number of oncology-focused small molecule drug discovery programs at Genentech. During this period he led a group responsible for developing novel cellular assays to report on drug activity and mechanism of action. His group contributed key mechanistic insights into the function of clinically approved drugs targeting the MAPK pathway and apoptosis. Dr. Anderson received a PhD in cell biology and biochemistry from the University of California, San Diego in conjunction with the Salk Institute where he was awarded the Martin D. Kamen Cell Biology Thesis Prize. He earned his BS degree in Biology from the University of Pittsburgh. Dr. Anderson has authored over 20 scientific publications including several in top-tier journals.
